Stockreport

Kitov Pharma Expands Planned NT-219 Clinical Program for Difficult to Treat Cancers

KITOV PHARAMCEUTICALS HOLDINGS LTD AMERICAN DEPOS  (KTOV) 
US:NASDAQ Investor Relations: kitovpharma.com
PDF Phase 1/2 Study to Evaluate NT-219 as Monotherapy Treatment of Advanced Solid Tumors, as well as in Combination with cetuximab for Treatment of Recurrent or [Read more]